01.12.2015 AURELIUS SE & Co. KGaA  DE000A0JK2A8

DGAP-News: AURELIUS acquires Allied Healthcare from Saga plc


 
DGAP-News: AURELIUS SE & Co. KGaA / Key word(s): Acquisition AURELIUS acquires Allied Healthcare from Saga plc 01.12.2015 / 13:51 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- AURELIUS acquires Allied Healthcare from Saga plc Munich / London, 1 December 2015 - AURELIUS Group (ISIN DE000A0JK2A8) ("AURELIUS"), the pan-European, mid-market investor, today announces the acquisition of Allied Healthcare ("the Company"), the UK's largest domiciliary care business and a leading provider of outsourced healthcare services to the English primary care sector, from Saga plc. The assets of Allied Healthcare acquired by AURELIUS comprise the following businesses: - Visiting Care: Britain's largest provider of domiciliary care by market share and a provider of complex care services in the home to individuals with critical needs, commissioned by both Local Authorities and Clinical Commissioning Groups (CCGs). - Primecare: A provider of outsourced primary healthcare services, such as out-of-hours GP services, walk-in centres and dental practices, on behalf of public sector bodies in England including CCGs and National Health Service (NHS) Trusts. Additionally, Allied Nursing provides an agency service for temporary clinical/medical staff. - Homecare Independent Living (HCIL): a home-based care and other housing and support services provider in which Allied Healthcare holds a majority interest, with operations in both Northern Ireland, where it is the leading domiciliary care provider, and the Republic of Ireland. Allied Healthcare is the leading domiciliary care business in the UK and has over 12,000 employees; in 2014 the Company recorded revenues of £282m (approx. EUR400m). Commenting on the acquisition, Dirk Markus, Chief Executive of AURELIUS Group, said: "As a non-core asset of Saga, Allied Healthcare is a special situation investment that meets the AURELIUS investment criteria on many levels. AURELIUS regards the acquisition of Allied as an opportunity to further grow and develop the Company's market leading position in the visiting care market - a critical service that supports the community care sector. Allied is a mature business with strong fundamentals; it has suffered from a number of legacy operational inefficiencies but we are confident that these can be streamlined." Tristan Nagler, Managing Director of AURELIUS in the UK, commented: "The enormous pressures facing vital UK care service providers like Allied Healthcare as a result of cuts to Local Authority funding and the impending introduction of the National Living Wage are well known. AURELIUS' operationally engaged approach means it is well positioned to give Allied the actively managed operational backing required to weather these challenges and ultimately build a strong and sustainable business in a sector that continues to grow year on year. "This is the second complex carve-out transaction that AURELIUS has made in the UK in Q4 2015; the deal further evidences our relevance for major UK corporates, such as Saga, seeking investment solutions for non-core assets." The acquisition of Allied Healthcare, combined with 10 other successful investments in 2015, will take AURELIUS' annualised sales to over EUR3bn. Last week, AURELIUS announced the approval of EUR166.3m of senior, unsecured convertible bonds due in 2020 which will provide the Group with a strong financial basis to support the organic and acquisitive growth of its investment portfolio. ABOUT AURELIUS AURELIUS is one of the leading European investment groups. From its offices in Munich, London, Stockholm and Madrid, AURELIUS acquires participations with development potential. Once under the AURELIUS umbrella, the acquisitions are given a long-term strategic orientation in order for them to fully develop their potential. Currently, the AURELIUS Group consists of 22 subsidiaries with locations in Europe, Asia, and the U.S.A. These include numerous traditional consumer brands, services businesses and a number of industrial enterprises. Companies are acquired based on strict investment criteria without focusing on any particular industry. Shares of AURELIUS SE & Co. KGaA are listed in the m:access segment of the Munich Stock Exchange and are traded on all German stock markets under ISIN DE000A0JK2A8. To find out more, visit www.aureliusinvest.com CONTACT Anke Banaschewski Investor Relations & Corporate Communications Phone +49 (89) 544799 - 0 Fax +49 (89) 544799 - 55 [email protected] About Allied Healthcare Allied Healthcare is the UK's largest domiciliary care business, with more than twice the market share of its nearest competitor, as well as a leading provider of healthcare services to the NHS and local government and the majority owner of a major Irish homecare provider. The company has over 100 community based branches with around 12,000 employees. It works with 140+ Local Authorities located across England, Scotland, and Wales, and 100+ NHS Clinical Commissioning Groups. For more information, visit www.alliedhealthcare.com/ --------------------------------------------------------------------------- 01.12.2015 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- 420061 01.12.2015


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 2.998,35 2.902,94 3.612,00 1.932,90 2.560,80 2.995,00 0,00
EBITDA1,2 272,56 65,72 80,30 167,60 249,70 154,40 0,00
EBITDA-Marge3 9,09 2,26 2,22 8,67 9,75 5,16
EBIT1,4 202,00 11,69 -84,20 222,70 115,80 29,40 0,00
EBIT-Marge5 6,74 0,40 -2,33 11,52 4,52 0,98 0,00
Jahresüberschuss1 484,49 -39,52 18,27 121,60 151,80 78,70 0,00
Netto-Marge6 16,16 -1,36 0,51 6,29 5,93 2,63 0,00
Cashflow1,7 -132,16 -50,00 -76,10 227,50 42,90 -41,50 0,00
Ergebnis je Aktie8 5,98 -1,43 -3,43 3,62 4,86 2,99 1,65
Dividende8 5,00 3,00 0,00 1,00 1,50 0,05 4,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2022 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: KPMG

INVESTOR-INFORMATIONEN
©boersengefluester.de
Aurelius Equity Opportunities
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A0JK2A 13,040 Halten 355,60
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
6,52 7,73 0,85 6,52
KBV KCV KUV EV/EBITDA
0,59 - 0,12 2,87
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,05 0,25 1,92 20.09.2023
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
11.05.2023 10.08.2023 10.11.2022 27.03.2023
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-11,15% -4,47% -4,12% -18,40%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu AURELIUS SE & Co. KGaA  ISIN: DE000A0JK2A8 können Sie bei EQS abrufen


Beteiligungen , A0JK2A , AR4 , HAM:AR4